Calcium Channel Blockers
Key Points
- CCBs block voltage-gated L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced cardiac workload.
- Dihydropyridines (amlodipine, nifedipine, nicardipine) primarily cause peripheral vasodilation and lower blood pressure.
- Nondihydropyridines (diltiazem, verapamil) also slow SA/AV node conduction and are the class IV antiarrhythmic CCBs used for rate control in arrhythmias.
- Do not abruptly discontinue; monitor for hypotension, peripheral edema, and constipation.
- Serious but less common risks include thrombocytopenia, symptomatic hypotension, and hyperglycemia.
- In infants under one year, most CCB pathways are avoided due to negative inotropic risk; nicardipine is a specialized postoperative exception in selected coarctation-repair hypertension contexts.
- Diltiazem and verapamil can raise simvastatin exposure; combined therapy generally requires low-dose simvastatin limits.
Pathophysiology
Calcium influx through L-type channels triggers smooth muscle contraction and cardiac action potential conduction. Blocking these channels reduces calcium entry, causing:
- Vascular smooth muscle relaxation → vasodilation → decreased blood pressure
- Decreased SA/AV node conduction velocity → slowed heart rate (nondihydropyridines)
- Reduced myocardial oxygen demand → antianginal effect
CCBs are particularly effective antihypertensives in older adults and non-Hispanic Black patients.
Classification
| Subclass | Examples | Primary Action |
|---|---|---|
| Dihydropyridines (DHP) | Amlodipine (Norvasc), nifedipine (Procardia), nicardipine (Cardene) | Peripheral vasodilation; minimal cardiac conduction effect; selected cerebral-vasospasm and migraine pathways in specialist-directed use |
| Nondihydropyridines (non-DHP) | Diltiazem (Cardizem), verapamil (Calan) | Cardiac rate control + vasodilation; SA/AV node slowing |
Nursing Assessment
NCLEX Focus
Never combine nondihydropyridines with beta-blockers without careful monitoring — additive negative chronotropic effect can cause heart block or severe bradycardia.
- Assess baseline blood pressure, heart rate, and ECG before initiation.
- If baseline heart rate is below about 60 bpm, clarify administration with the provider before dosing.
- Assess for heart failure, sick sinus syndrome, severe hypotension, or history of MI — relative/absolute contraindications.
- Assess for pulmonary-congestion history and hepatic impairment when selecting dose and monitoring intensity.
- In pediatric use, verify age and indication carefully; avoid routine CCB use in infants under one year and avoid negative-inotropy burden in infant heart-failure states unless specialist-directed exception exists.
- Monitor for peripheral edema, which is common with DHP agents (especially amlodipine).
- Monitor for uncommon but serious adverse effects including thrombocytopenia and hyperglycemia.
- Assess concurrent medications: diltiazem/verapamil inhibit CYP3A4 — significant drug interactions with statins (simvastatin), digoxin, and cyclosporine.
- For non-DHP antiarrhythmic use, assess for concomitant beta-blocker therapy because additive AV-node suppression can cause severe bradycardia or heart block.
Nursing Interventions
- Monitor blood pressure and heart rate before each dose; hold if systolic BP <90 mmHg or HR <60 bpm per protocol.
- Instruct patients not to crush or chew extended-release formulations.
- Teach patients not to abruptly discontinue — may precipitate rebound chest pain or angina.
- Grapefruit juice inhibits CYP3A4 metabolism of CCBs — instruct patients to avoid grapefruit.
- Review herb-supplement use, including St. John’s wort, because interaction burden can alter effect or safety.
- Manage constipation (especially with verapamil): increase fiber, fluids, and activity.
- Administer with food when GI intolerance occurs and reinforce reporting of severe headache, dizziness, flushing, nausea, or worsening leg swelling.
- Use continuous ECG/hemodynamic monitoring for IV diltiazem/verapamil infusions and reassess frequently during titration.
- Verify exact non-DHP product/formulation during medication reconciliation because diltiazem extended-release products are not always bioequivalent.
Avoid Nondihydropyridines + Beta-Blockers
Combination of diltiazem or verapamil with beta-blockers can cause complete heart block, severe bradycardia, and hemodynamic collapse. Never administer IV verapamil within hours of IV beta-blocker.
Abrupt Discontinuation
Abrupt discontinuation of CCBs, especially in angina patients, can precipitate rebound chest pain and myocardial ischemia.
Pharmacology
| Drug | Dose (Adult) | Key Nursing Considerations |
|---|---|---|
| Amlodipine (Norvasc) | 5–10 mg orally daily | Once daily; peripheral edema common; well-tolerated in renal disease |
| Nifedipine (Procardia) | IR: 10–20 mg 3×/day; SR: 30–60 mg daily | Extended-release preferred; avoid in acute MI; avoid grapefruit |
| Diltiazem (Cardizem) | 30–360 mg/day in divided doses | Rate control; monitor HR; CYP3A4 inhibitor; avoid high-dose simvastatin co-use (commonly limit to 10 mg/day) |
| Verapamil (Calan) | 80–360 mg/day | Most potent AV node effect; constipation (constipation) common; avoid with beta-blockers; avoid high-dose simvastatin co-use (commonly limit to 10 mg/day) |
Clinical Judgment Application
Clinical Scenario
A patient with hypertension on amlodipine develops bilateral ankle swelling and asks if they should stop the medication.
- Recognize Cues: Peripheral edema is a known side effect of dihydropyridine CCBs.
- Analyze Cues: Edema due to vasodilation; not cardiac in origin, but needs assessment.
- Prioritize Hypotheses: Confirm medication side effect vs. new cardiac or renal cause.
- Generate Solutions: Assess for other edema causes; reassure patient; do not stop without provider guidance.
- Take Action: Document and notify provider; consider dose reduction or alternative antihypertensive.
- Evaluate Outcomes: Edema resolves with intervention; blood pressure remains controlled.
Related Concepts
- antihypertensives - Broader antihypertensive drug class framework.
- beta-blockers - Contraindicated combination with verapamil/diltiazem.
- hypertension-assessment-and-management - Clinical indication and treatment protocols.
- coronary-artery-disease - Antianginal indication for CCBs.
- systematic-ecg-interpretation-and-dysrhythmia-triage - Rate control indication for nondihydropyridines.
- congenital-heart-defects-acyanotic-and-cyanotic-patterns - Coarctation repair pathways may include specialist-directed postoperative nicardipine for persistent hypertension.
Self-Check
- What is the key clinical difference between dihydropyridine and nondihydropyridine CCBs?
- Why should grapefruit be avoided with CCBs?
- What drug-drug interaction makes nondihydropyridines dangerous when combined with beta-blockers?